DK2917360T3 - Antistoffer mod S. aureus-overflade-determinanter - Google Patents

Antistoffer mod S. aureus-overflade-determinanter Download PDF

Info

Publication number
DK2917360T3
DK2917360T3 DK13852597.7T DK13852597T DK2917360T3 DK 2917360 T3 DK2917360 T3 DK 2917360T3 DK 13852597 T DK13852597 T DK 13852597T DK 2917360 T3 DK2917360 T3 DK 2917360T3
Authority
DK
Denmark
Prior art keywords
antibodies
surface determinants
aureus surface
aureus
determinants
Prior art date
Application number
DK13852597.7T
Other languages
English (en)
Inventor
Bret Sellman
Christine Tkaczyk
Partha S Chowdhury
Lei Hua
Peter Pavlik
Rebecca Buonpane
Chew-Shun Chang
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Application granted granted Critical
Publication of DK2917360T3 publication Critical patent/DK2917360T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK13852597.7T 2012-11-06 2013-11-06 Antistoffer mod S. aureus-overflade-determinanter DK2917360T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723137P 2012-11-06 2012-11-06
US201361782405P 2013-03-14 2013-03-14
PCT/US2013/068624 WO2014074540A2 (en) 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants

Publications (1)

Publication Number Publication Date
DK2917360T3 true DK2917360T3 (da) 2020-03-30

Family

ID=50685304

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13852597.7T DK2917360T3 (da) 2012-11-06 2013-11-06 Antistoffer mod S. aureus-overflade-determinanter

Country Status (16)

Country Link
US (3) US9879070B2 (da)
EP (2) EP2917360B1 (da)
JP (2) JP6694269B2 (da)
KR (1) KR102288394B1 (da)
CN (2) CN104968797B (da)
AU (2) AU2013341361A1 (da)
BR (1) BR112015010125A2 (da)
CA (1) CA2890427C (da)
DK (1) DK2917360T3 (da)
ES (1) ES2776179T3 (da)
HU (1) HUE049012T2 (da)
MX (2) MX375324B (da)
PL (1) PL2917360T3 (da)
RU (1) RU2698131C2 (da)
SG (2) SG10201703678TA (da)
WO (1) WO2014074540A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201370T1 (hr) 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
KR20210083389A (ko) 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
WO2015187779A1 (en) * 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
US20180017559A1 (en) * 2014-08-12 2018-01-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
FR3033333A1 (fr) * 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
CN107873034A (zh) * 2015-04-17 2018-04-03 阿尔萨尼斯生物科学有限责任公司 抗金黄色葡萄球菌抗体组合制剂
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
CN105424930A (zh) * 2015-11-23 2016-03-23 天津科技大学 一种快速检测金黄色葡萄球菌的方法
CA3076632A1 (en) * 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
JP7525471B2 (ja) 2018-07-24 2024-07-30 メディミューン，エルエルシー Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体
TWI895248B (zh) 2018-10-09 2025-09-01 美商麥迪紐有限責任公司 針對金黃色葡萄球菌白血球毒素的抗體
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
KR20210126641A (ko) 2019-02-12 2021-10-20 리제너론 파아마슈티컬스, 인크. 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
CN113811544A (zh) 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR102504175B1 (ko) * 2020-06-17 2023-02-28 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법
KR102397684B1 (ko) * 2019-12-09 2022-05-13 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법
KR102674109B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드, 이를 포함하는 면역분석 장치 및 이를 이용한 면역분석 방법
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
KR102674120B1 (ko) * 2021-01-18 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 면역분석 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017198A (en) * 1931-10-17 1935-10-15 Anglada Motor Corp Cuff valve engine
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
PT1377314E (pt) * 2001-01-26 2012-01-02 Inhibitex Inc Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções
KR20060034231A (ko) 2003-06-06 2006-04-21 메디뮨 인코포레이티드 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
AU2004266242A1 (en) 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US20080050361A1 (en) 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
WO2007101441A1 (en) 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20080131457A1 (en) * 2006-06-12 2008-06-05 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
CA2667788A1 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9526774B1 (en) * 2006-11-06 2016-12-27 Microvax, Llc Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus
SG188102A1 (en) * 2008-01-31 2013-03-28 Trinity College Dublin Treatment of microbial infections
EP2291196A4 (en) * 2008-05-12 2012-05-30 Strox Biopharmaceuticals Llc FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS
WO2010005513A2 (en) * 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
EP2341929B1 (en) * 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
WO2011019423A2 (en) * 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
SA110310528B1 (ar) * 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
JP6192294B2 (ja) * 2009-07-15 2017-09-06 エーアイエムエム セラピューティクス ベー．フェー． グラム陽性菌特異的結合化合物
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2011079308A2 (en) * 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP2555794A4 (en) * 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
EP2614074A1 (en) * 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US20120202047A1 (en) 2011-02-07 2012-08-09 Baker Hughes Incorporated Nano-coatings for articles
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
RS60499B1 (sr) * 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
JP6670106B2 (ja) * 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
KR20210083389A (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CA2898472C (en) * 2013-02-15 2023-03-07 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
WO2015057893A2 (en) * 2013-10-15 2015-04-23 The Texas A&M University System Compositions and the use of a fibrinogn binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery
WO2015106226A2 (en) * 2014-01-10 2015-07-16 University Of Rochester Diagnostic device and method for detection of staphylococcus infection
WO2015112895A2 (en) * 2014-01-24 2015-07-30 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
WO2015187779A1 (en) * 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
CN107873034A (zh) 2015-04-17 2018-04-03 阿尔萨尼斯生物科学有限责任公司 抗金黄色葡萄球菌抗体组合制剂
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
BR112018077540A2 (pt) * 2016-07-08 2019-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
JP7525471B2 (ja) * 2018-07-24 2024-07-30 メディミューン，エルエルシー Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体
BR112021006622A2 (pt) * 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
TWI895248B (zh) * 2018-10-09 2025-09-01 美商麥迪紐有限責任公司 針對金黃色葡萄球菌白血球毒素的抗體
CN113811544A (zh) * 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染

Also Published As

Publication number Publication date
RU2698131C2 (ru) 2019-08-22
US20190016787A1 (en) 2019-01-17
PL2917360T3 (pl) 2020-06-29
EP2917360B1 (en) 2020-01-08
KR20150094621A (ko) 2015-08-19
MX2015005477A (es) 2015-11-30
HUE049012T2 (hu) 2020-09-28
AU2013341361A1 (en) 2015-06-04
JP6694269B2 (ja) 2020-05-13
BR112015010125A2 (pt) 2017-08-22
CN109553681A (zh) 2019-04-02
US11447543B2 (en) 2022-09-20
HK1215054A1 (en) 2016-08-12
WO2014074540A2 (en) 2014-05-15
CN104968797B (zh) 2018-11-30
EP2917360A2 (en) 2015-09-16
HK1215452A1 (zh) 2016-08-26
EP3640338A1 (en) 2020-04-22
SG11201503232TA (en) 2015-05-28
MX375324B (es) 2025-03-06
CA2890427A1 (en) 2014-05-15
JP2016507470A (ja) 2016-03-10
SG10201703678TA (en) 2017-06-29
ES2776179T3 (es) 2020-07-29
EP2917360A4 (en) 2017-01-25
RU2015121624A (ru) 2016-12-27
RU2019122610A (ru) 2020-02-18
WO2014074540A3 (en) 2014-07-10
CN104968797A (zh) 2015-10-07
CA2890427C (en) 2022-05-31
US9879070B2 (en) 2018-01-30
KR102288394B1 (ko) 2021-08-09
US10730934B2 (en) 2020-08-04
AU2018241107B2 (en) 2020-09-17
US20200407429A1 (en) 2020-12-31
JP2019089801A (ja) 2019-06-13
US20150291685A1 (en) 2015-10-15
MX2022008079A (es) 2022-07-11
AU2018241107A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
CY2024011I1 (el) Αντισωματα anti-fcrn
DK2917360T3 (da) Antistoffer mod S. aureus-overflade-determinanter
DK2934584T3 (da) Anti-gdf15-antistoffer
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
DK2707385T3 (da) RSV-F-præfusionsantigener
HRP20181874T1 (hr) Anti-cxcr3 protutijela
DK2906597T3 (da) Antistoffer mod beta-amyloid
HUE040048T2 (hu) Bálázó
DK2855530T3 (da) Anti-transglutaminase 2-antistoffer
DK2828292T3 (da) Jcv-neutraliserende antistoffer
BR112013030897A2 (pt) composição.
DK2935330T3 (da) Anti-notch3-antistoffer
EP2920370A4 (en) POST
FR2986872B1 (fr) .
FR2985007B1 (fr) Regenerateur.
FR2978994B1 (fr) .
EE01200U1 (et) Lillepott
BR112014027645A2 (pt) 5-halogenopirazol bifenilcarboxamidas.
ES2396651B2 (es) Material biosanitario antiulcera.
FR2980994B1 (fr) Prehenseur multi-plaquettes.
ES1077197Y (es) Jardinera.
ES1074539Y (es) Mandil.
ES1074780Y (es) Columna-luminaria.
FR2999675B1 (fr) Electro-clapet ameliore
ES1075012Y (es) Embudo.